Phio Pharmaceuticals Corp.
PHIOHealthcare|Biotechnology|US
$0.80
+0.00 (+0.16%)
DCF Value
$3.45
Tangible Book / Share
$0.74
Cash / Share
$0.91
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05902520 Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors | HNSCC, Melanoma | P1 | Active | 18 | RCT, Open-label | DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2 |
| NCT06014086 Intratumoral PH-762 for Cutaneous Carcinoma | Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin | P1 | Completed | 22 | Open-label | PH-762 |